20/20 Biolabs, Inc. Common Stock (AIDX)vsEli Lilly and Company (LLY)
AIDX
20/20 Biolabs, Inc. Common Stock
$0.20
+0.25%
HEALTHCARE · Cap: $2.62M
LLY
Eli Lilly and Company
$1,433.55
-0.82%
HEALTHCARE · Cap: $1.27T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 4237818% more annual revenue ($86.46B vs $2.04M). LLY leads profitability with a 31.9% profit margin vs -285.0%. LLY earns a higher WallStSmart Score of 74/100 (B).
AIDX
Hold36
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 36.5% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 51.2%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -354.6% — below average capital efficiency
Negative free cash flow — burning cash
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 36.5% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.
Key Dynamics to Monitor
AIDX profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.39 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 36/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?